Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients (Q49056677)

18 February 2018

http://europepmc.org/abstract/MED/25053248

title

Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients (English)

1 reference

18 February 2018

http://europepmc.org/abstract/MED/25053248

main subject

antibiotic

0 references

corrigendum / erratum

Erratum to: Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients.

0 references

author

Jordi Rello

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053248%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Andrew A. Udy

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053248%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Jason A. Roberts

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053248%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Jeffrey Lipman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053248%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Murat Akova

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053248%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Despoina Koulenti

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053248%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Andrew Rhodes

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053248%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

1

Jan J De Waele

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053248%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

M Bassetti

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053248%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

G Dimopoulos

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053248%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

M Kaukonen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053248%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

C Martin

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053248%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

P Montravers

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053248%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

T Starr

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053248%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

S C Wallis

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053248%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

publication date

23 July 2014

1 reference

18 February 2018

http://europepmc.org/abstract/MED/25053248

published in

Intensive Care Medicine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053248%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053248%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053248%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

1340-1351

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053248%20AND%20SRC:MED&resulttype=core&format=json

Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections

13 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Year in review in Intensive Care Medicine 2012. II: Pneumonia and infection, sepsis, coagulation, hemodynamics, cardiovascular and microcirculation, critical care organization, imaging, ethics and legal issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Antibiotic rotation and development of gram-negative antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Year in review in Intensive Care Medicine 2013: III. Sepsis, infections, respiratory diseases, pediatrics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Identifying patients at risk for augmented renal clearance in the ICU - limitations and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Case-control study of drug monitoring of β-lactams in obese critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

APACHE II: a severity of disease classification system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Clinical implications of antibiotic pharmacokinetic principles in the critically ill.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Optimization of meropenem dosage in the critically ill population based on renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Does prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Augmented renal clearance in the critically ill: how to assess kidney function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Augmented creatinine clearance in traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

ARC--augmented renal clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Pharmacokinetics of beta-lactam antibiotics in patients with intra-abdominal disease: a structured review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Dose modulation: a new concept of antibiotic therapy in the critically ill patient?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Daily serum piperacillin monitoring is advisable in critically ill patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Therapeutic drug monitoring of piperacillin-tazobactam using spent dialysate effluent in patients receiving continuous venovenous hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-014-3403-8

Do we understand the impact of altered physiology, consequent interventions and resultant clinical scenarios in the intensive care unit? The antibiotic story

21 January 2018

1 reference

12 December 2020

Can PK/PD be used in everyday clinical practice

1 reference

12 December 2020

Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia

1 reference

12 December 2020

Subtherapeutic Initial β-Lactam Concentrations in Select Critically Ill Patients

1 reference

12 December 2020

Changes in vancomycin pharmacokinetics in critically ill infants

1 reference

12 December 2020

Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy

1 reference

12 December 2020

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine

1 reference

12 December 2020

10.1007/S00134-014-3403-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053248%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

1 reference